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Introduction
Interest in the evaluation of disease screening has
grown in recent years and the importance of consider-
ing both the scientific validity and overall benefits of
screening, as well as establishing cost-effective, ethi-
cal and equitable policies for population screening is
increasingly being recognised. Although insufficient
evidence is available to support the provision of most
screening procedures at a population level, a few have
been shown to be highly effective and are now well
established in many countries. Screening for cervical
cancer using the Papanicolaou (Pap) smear is one such
example, where the evidence supporting its effective-
ness is so strong that death from the disease among
women under the age of 65 years is considered to be
avoidable.1 This issue is topical and of increasing pub-
lic interest in Hong Kong, as reflected by some recent
articles in both the Chinese and English daily press.2-7
Natural history and epidemiology of cervical
cancer
Long-term studies have demonstrated that invasive
disease arises as a consequence of progression from
mild dysplasia through severe dysplasia to carcinoma
in situ.8 Richart introduced the commonly used classi-
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fication system for these pre-invasive lesions as dif-
ferent grades of cervical intraepithelial neoplasia (CIN
I to III).9 Although mild dysplasia (CIN I) frequently
regresses to normal, CIN III, once established, rarely
exhibits spontaneous regression.10 Therefore, for every
patient with invasive cervical cancer there are approxi-
mately four patients with carcinoma in situ and more
than 10 patients with low grade CIN.11 Overall, up
to three quarters of cases of CIN I or II progress to
CIN III and 10% to16% eventually progress to invasive
cancer.12
Over the past few decades, overall mortality from
cervical cancer has been falling in most countries, al-
though the rate has increased in the younger age groups
in some populations.13 It remains a significant cause
of morbidity and mortality, being the second most
common form of cancer in women worldwide.14 There
is wide variation in the reported incidence of invasive
disease between populations, ranging from 7% in one
generation of women in Colombia, to 0.35% for the
same generation in the non-Jewish population of Is-
rael.15 Apart from differences in diagnostic and report-
ing patterns, the two major factors contributing to this
variation are considered to be differences in sexual
practice, and differences in access to organised cervi-
cal cancer screening programmes. There is good evi-
dence that sexual behaviour patterns such as age at
first intercourse and the number of lifetime sexual part-
ners of the woman and of her husband play an impor-
tant role in the aetiology of cervical cancer. These
practices determine the woman’s risk of acquiring a
sexually transmitted disease, and customs vary over
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time and between population groups. Thus, certain
population subgroups, such as nuns and groups with
strict practices of abstinence and monogamy, have long
been noted to have very low rates of cervical cancer.8
In contrast, populations with higher rates of sexually
transmitted diseases, reflecting a greater level of extra-
marital sexual activity, have higher mortality rates from
cervical cancer.16
The incidence of cervical cancer increases with age,
starting to rise in women between the ages of 30 and
35 years in most countries, and reaching a peak at about
50 to 60 years. Apart from age, the other main factors
which are strongly associated with invasive cancer
include the following:
Infection with human papillomavirus
Both epidemiological and molecular studies provide
support for human papillomavirus (HPV), particularly
HPV 16, 18, 45 and 56, as a primary aetiological
factor in cervical cancer.17,18 However, since exposure
to HPV in young sexually active women is very com-
mon and infection with oncogenic viral types exceeds
the number of cases of invasive cancer, other cofactors
must play a part in cervical carcinogenesis.
The lifetime number of sexual partners
Women who report three or more lifetime sexual
partners have a two- to three-fold increased risk of
developing cervical cancer, compared with those who
report only one partner. The risk increases to nine-fold
for women reporting 10 or more partners.19
Use of oral contraceptives
Several studies have documented an association be-
tween the duration of oral contraceptive use and both
CIN and cervical cancer.20 The risk is increased in those
who start using oral contraception before the age of
25 or who use it for 7 or more years.
Smoking
Several observational studies have shown an association
between smoking and cervical cancer, with an estimated
two-fold increased risk for current smokers.21 The risk
increases with the amount and duration of smoking. The
association persists after adjusting for sexual practice as
a potential confounder, but is weakened after adjusting
for infection with HPV.22
Screening for cervical cancer
Primary prevention of cervical cancer is not possible
in the foreseeable future. However, several features of
the disease make it an ideal target for a screening pro-
gramme. It has a long pre-invasive phase that may ex-
tend from 10 to 15 years. A safe, widely acceptable
and inexpensive test, the Pap smear, is available to
detect early-stage disease, and effective treatment of
early-stage lesions can be accomplished with mini-
mally invasive techniques.
Evidence for the effectiveness of screening comes
from descriptive studies, which show a decline in both
the incidence and mortality from invasive cervical can-
cer following the introduction of organised screening
programmes.8,23,24 Finland, Iceland and Sweden have
implemented nationwide ‘population-based organised’
screening programmes since the 1960s. In these coun-
tries, the protective effect of two or more smears is
clearly demonstrated25 and the number of deaths from
cervical cancer have been reduced by 80%.26 There
have also been several case-control studies document-
ing a reduction in the relative risk for invasive dis-
ease in women who have undergone Pap smear screen-
ing.27-29 Most of these studies show a 90% reduction in
the risk of invasive disease with screening intervals of
up to 3 years.
The extent of risk reduction is partly dependent on
the screening interval. Data from large screening pro-
grammes in European and North American centres
have been analysed by the working group of the Inter-
national Agency for Research on Cancer and used to
quantify the reduction in the probability of develop-
ing cervical cancer with varying screening intervals
(Table).30 The data shows that after one negative Pap
smear, screening every 3 years accomplishes about the
same effect as screening annually. Furthermore, even
screening once every 10 years can reduce the inci-
dence of invasive cancer by almost two thirds. Hence,
at a population level the achievement of adequate cov-
erage of women at risk is a more significant determi-
nant of risk reduction than the frequency of screening.31
Targeting women who have never had a Pap smear
Table. Reduction in cumulative rate of invasive cer-
vical cancer in 35- to 64-year-old women screened
at different frequencies*
Interval between Reduction in Number of
screenings (years) cumulative tests
 incidence (%)
1 93.5 30
2 92.5 15
3 90.8 10
5 83.6 6
10 64.1 3
*Assuming the woman has had at least one previous screen
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will have a much larger impact on reducing disease
incidence and mortality, than screening more fre-
quently those who have already been screened. In
practice, despite the success of some screening pro-
grammes, others such as the early ones implemented
in the United Kingdom and Norway have not been
successful.32 The main reasons cited for such failures
are poor programme coordination and non-implemen-
tation of policy. In the United Kingdom, resources
were concentrated on more frequent screening of
younger women, rather than trying to achieve regular
coverage for the entire population.33 In Norway, only
a small proportion of the population was covered by
an organised programme.
Effective cervical screening programmes
The essential elements of an effective cervical cancer
screening programme, including organisation, account-
ability and commitment, are well documented.31,32,34
Cases of invasive cervical cancer arising as a result of
administrative and procedural failures thus cannot be
justified in any developed country. The success of
screening is dependent on factors which include the
provision of adequate resources and the adoption of
quality control measures. Ensuring that smears are
promptly examined and the results fed back accurately
requires considerable resources, both in terms of
laboratories and human resources. Among screening
smears, more than 90% of samples are expected to be
normal, and some positive cases are likely to be missed.
In order to minimise such false negative results, inde-
pendent rescreening and quality assessment must be
an integral part of the programme.33
Once abnormalities are detected, agreed guidelines
for follow-up and clear lines of responsibility for
doing this are essential. Several studies have high-
lighted inadequate follow-up as a problem which is
more common than the problem of false negatives, and
is responsible for a proportion of cases of invasive
cervical cancer.35 In one study, omission by clinicians
and administrative errors accounted for more than
90% of cases of documented inadequate follow-up, and
only a small proportion of cases were attributable to
the patients themselves.36 Furthermore there is increas-
ing evidence that in women who have had conserva-
tive treatment for cervical intraepithelial neoplasia,
regular and long-term follow-up is necessary, as the
risk of invasive cancer remains high.37
Although financial and technical considerations are
important, the main difference between effective pro-
grammes and those which fail is in their level of or-
ganisation and management.32 The recognition by the
World Health Organization that poor management and
the implementation of inappropriate policies are re-
sponsible for the failure of some screening programmes
has prompted the Western Pacific Regional Office to
adopt managerial guidelines.38 The purpose of these is
to assist in the planning, development, management,
and monitoring of programmes for the early detection
of cervical cancer.
An organised screening programme is more likely
to target women at high risk compared to one where
screening is opportunistic, and it can reduce the inci-
dence of invasive cancer by up to 90%.39 There is in
fact a strong correlation between the organisation of
screening and changes in disease incidence.40,41 A well-
managed programme also has several other advantages.
Internationally there is evidence that older women and
those with low socio-economic status have a higher
than average risk for cervical cancer and are less likely
to take up preventive health services.42 Increasing cov-
erage by targeting will tend to attract these women
more, and can therefore contribute to a reduction in
health inequalities.43 Furthermore, if most women at-
tending screening are those at lower risk, more false
positives are likely to arise, resulting in additional
medical work, unnecessary anxiety, and possibly ia-
trogenic disease. This also wastes resources and re-
duces the cost-effectiveness of screening.44,45
Cervical cancer in Hong Kong
Cervical cancer is an important public health problem
in Hong Kong. Compared to other industrialised coun-
tries, Hong Kong has a moderately high mortality rate
for cervical cancer,46 and is cited as a high-risk area
for this by the International Agency for Cancer Re-
search.15 In contrast, Hong Kong women are at lower
risk of other common cancers, such as those of the
breast and lung, compared with their counterparts in
most western countries. The incidence of clinical can-
cer increases with age and, reaches a peak in the 60 to
65 years age group (Fig 1). It is the fourth most com-
mon newly diagnosed cancer in local women,47 in
contrast to being ranked eighth in the UK in 1988.31
Of 159 deaths from the disease in 1995,48 one half oc-
curred in the 15 to 64 years age group, where it should
have been avoidable.
There has been a slow overall decline in incidence
and mortality from cervical cancer in Hong Kong over
the past 15 years (Fig 2). The decreasing tendency is
more apparent in middle-age rather than in the elderly
(Fig 1), and is less marked than the downward trend
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seen in areas where there are well-organised screen-
ing programmes. The unexplained increase in mortal-
ity among younger women, which is seen in some
countries, is not yet apparent in Hong Kong.
At present there is no centrally organised, system-
atic, population-based cervical screening  programme.
Most screening activity is either opportunistic or offered
as a part of a general well woman check up by various
health care providers, each with their own agenda. It is
estimated that about two thirds of Pap smears are carried
out by the Family Planning Association and the Depart-
ment of Health, while the rest are done in the private
sector. There is no locally developed policy on screen-
ing, and as yet there are no guidelines from the major
local medical organisations such as the Hong Kong
Medical Association or the Hong Kong College of Ob-
stetricians and Gynaecologists.
Health surveys by the Family Planning Associa-
tion of Hong Kong in 1992 found that the 1 year
coverage of screening among women under the age
of 60 years is around 30%.49,50 The highest coverage
was among the 30- to 49-year-olds, while women over
the age of 50 years, who are at higher risk, had the
lowest coverage (20%). However, there remain many
unanswered questions. We do not know what the fre-
quency of screening is among those who are currently
Fig 1. Trends in cervical cancer mortality rate by age group
Source: Director of Health Annual Reports, 1981/82 - 1994/95; standardised to world standard population, linear trend line
fitted
Fig 2. Age-standardised mortality rates for cervical cancer in Hong Kong, 1981-1994
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screened, nor whether they are the women with other
risk factors. More research is needed to assess the tech-
nical and quality control aspects of screening. There
is no local information on the acceptability of the
present arrangements for screening. Most important
in terms of minimising the population impact of the
disease is the need to consider the most effective means
of achieving high coverage of the population at risk.
This is a major challenge, because of the heterogene-
ous nature of Hong Kong’s mixed medical economy.
The way forward
While more local research is needed, we should also
take heed of what has been learned the hard way in
other countries. We need a local policy with clear ob-
jectives which define the target groups and screening
arrangements, and which is linked to a continuing
evaluation programme. In the absence of a centralised
population register, various approaches for the imple-
mentation of such a policy need to be considered. These
may include educational approaches that are aimed at
both the public and health professionals, or the use of
incentives, such as service payments. If there are pro-
fessional or financial obstacles to the achievement of
coverage through current health care providers, then
new managed care contracts should be considered to
provide cervical screening. Adequate resources for
health promotion to target at-risk women, and facili-
ties for the prompt examination and reporting of smears
should be made available. Finally, locally developed
guidelines that are linked to an audit programme should
be disseminated to ensure that standardised methods
are used for taking, analysing and reporting smears,
and that adequate quality control arrangements are in
place. A coordinated, population-wide approach to
screening is the only way to prevent further avoidable
deaths from cervical cancer.
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